Article ; Online: Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry.
International journal of cardiology
2013 Volume 168, Issue 3, Page(s) 2522–2527
Abstract: Background: Outcome of sirolimus-eluting stent (SES) in patients treated with an antivitamin K ... among 15,147 recipients of SES, included in the worldwide e-SELECT registry, only from those centers ...
| Abstract | Background: Outcome of sirolimus-eluting stent (SES) in patients treated with an antivitamin K (VKA) agent before the PCI procedure is unknown. Methods: A total of 7651 patients were selected among 15,147 recipients of SES, included in the worldwide e-SELECT registry, only from those centers which included at least one patient requiring VKA: 296 were pretreated with a VKA agent (VKA group), whereas 7355 patients from the same enrolling medical centers were not (NON-VKA group). The rates of 1) major adverse cardiac events (MACE), including all-cause deaths, myocardial infarction (MI) and target lesion revascularization, 2) stent thrombosis (ST) and 3) major bleeding (MB) in the 2 study groups were compared at 1, 6 and 12 months. Results: The patients in VKA group were on average older as compared to those in NON-VKA group (67.7 ± 9.9 vs.62.9 ± 10.7, P<0.001). The indications for pre-procedural anticoagulation were atrial fibrillation in 177 (59.8%), presence of a prosthetic valve in 21 (7.1%), embolization of cardiac origin in 17 (5.7%), pulmonary embolism or deep vein thrombosis in 17 (5.7%), and miscellaneous diagnoses in 64 (21.6%) patients. At 1 year, the rates of MACE and MB were higher in the VKA vs. the NON-VKA group (8.3% and 3% vs. 5.3% and 1.2%, P<0.04 and P<0.002, respectively). The 1-year rates of definite and probable ST were remarkably low in both groups (0.38% vs. 1.1%, p=0.4). Conclusions: Selected patients anticoagulated with VKA agent may safely undergo SES implantation. Those patients may receive a variety of APT regimen at the cost of a moderate increased risk of MB. |
|---|---|
| MeSH term(s) | Aged ; Drug-Eluting Stents ; Female ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/therapeutic use ; Prosthesis Implantation ; Registries ; Sirolimus/administration & dosage ; Thrombosis/prevention & control ; Time Factors ; Treatment Outcome ; Vitamin K/antagonists & inhibitors |
| Chemical Substances | Platelet Aggregation Inhibitors ; Vitamin K (12001-79-5) ; Sirolimus (W36ZG6FT64) |
| Language | English |
| Publishing date | 2013-10-03 |
| Publishing country | Netherlands |
| Document type | Comparative Study ; Journal Article |
| ZDB-ID | 779519-1 |
| ISSN | 1874-1754 ; 0167-5273 |
| ISSN (online) | 1874-1754 |
| ISSN | 0167-5273 |
| DOI | 10.1016/j.ijcard.2013.03.064 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1673: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.